FM
AUTL

Frazier Management’s Autolus Therapeutics AUTL Stock Holding History

Frazier Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,746,857
Closed -$19.4M – 7
2021
Q4 		$19.4M Buy
3,746,857
+216,200
+6% +$1.3M 1.5% 23
2021
Q3 		$23.1M Buy
3,530,657
+1,246,691
+55% +$7.88M 1.85% 16
2021
Q2 		$15.2M Buy
+2,283,966
New +$14.2M 1.4% 17

Other funds holding AUTL

Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Frazier Management's AUTL Position: Q1 2022 in Review

Frazier Management sold out of Autolus Therapeutics (AUTL) in Q1 2022, closing a stake of 3,746,857 shares — an estimated $19.4M sold.

Frazier Management first reported a position in AUTL in Q2 2021 and held it in 3 quarters. The position peaked at $23.1M in Q3 2021. 66 funds tracked by Wall St. Rank hold AUTL as of Q1 2022.

  • Frazier Management reported no remaining Autolus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 3,746,857 Autolus Therapeutics shares in Q1 2022, an estimated $19.4M.
  • Frazier Management first reported a position in Autolus Therapeutics in Q2 2021 and held it in 3 quarters.
  • Frazier Management's Autolus Therapeutics position peaked at $23.1M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.